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AbsTrACT
Objectives To assess the efficacy of golimumab in 
combination with methotrexate (MTX) versus MTX 
monotherapy in psoriatic arthritis (Psa) dactylitis.
Methods Multicentre, investigator- initiated, 
randomised, double- blind, placebo- controlled, parallel- 
design phase 3b trial in 11 Portuguese rheumatology 
centres. Patients with Psa along with active dactylitis 
and naive to MTX and biologic disease- modifying 
antirheumatic drugs (bDMaRDs) were randomly assigned 
to golimumab or placebo, both in combination with 
MTX. The primary endpoint was Dactylitis severity score 
(Dss) change from baseline to week 24. Key secondary 
endpoints included Dss and leeds Dactylitis index (lDi) 
response, and changes from baseline in the lDi and MRi 
dactylitis score. analysis was by intention- to- treat for the 
primary endpoint.
results Twenty- one patients received golimumab 
plus MTX and 23 MTX monotherapy for 24 weeks. 
One patient from each arm discontinued. Patient 
inclusion was halted at 50% planned recruitment due 
to a favourable interim analysis. Median baseline Dss 
was 6 in both arms. By week 24, patients treated with 
golimumab plus MTX exhibited significantly greater 
improvements in Dss relative to MTX monotherapy 
(median change of 5 vs 2 points, respectively; p=0.026). 
in the golimumab plus MTX arm, significantly higher 
proportions of patients achieved at least 50% or 
70% improvement in Dss and 20%, 50% or 70% 
improvement in lDi in comparison to MTX monotherapy.
Conclusions The combination of golimumab and 
MTX as first- line bDMaRD therapy is superior to MTX 
monotherapy for the treatment of Psa dactylitis.
Trial registration number nCT02065713
InTrOduCTIOn
Psoriatic arthritis (PsA) is a chronic inflamma-
tory disease of substantial phenotypic hetero-
geneity. Such heterogeneity poses challenges in 
Key messages
What is already known about this subject?
 ► Psoriatic dactylitis is associated with higher 
psoriatic arthritis disease activity and articular 
erosions.
 ► Treatment algorithms are controversial due to 
the absence of randomised controlled trials 
assessing dactylitis as a primary endpoint, 
especially in the context of methotrexate (MTX) 
versus tumour necrosis factor inhibitors /MTX 
combination.
What does this study add?
 ► The GO- DACT trial showed that the 
combination of golimumab plus MTX is 
associated with significantly greater clinical 
improvements in dactylitis in comparison with 
MTX monotherapy.
How might this impact on clinical practice or 
future developments?
 ► GO- DACT provides evidence that combining 
golimumab plus MTX is more efficacious than 
MTX monotherapy in improving psoriatic 
arthritis (PsA) dactylitis.
 ► GO- DACT showed that application of the 
innovative Dactylitis Severity Score (DSS) and 
Leeds Dactylitis Index (LDI) response indices 
(DSS20, 50 and 70 and LDI20, 50 and 70) 
allowed discrimination between treatment 
arms, which could be useful for future PsA  
trials.
 ► The GO- DACT trial provides data in an area 
of previously limited evidence to inform 
the creation of clinically useful treatment 
algorithms, aiming at the optimal care of 
patients with PsA.
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management, particularly in deriving a sufficient evidence base 
to address clinical subtypes. Dactylitis is a hallmark of PsA1 for 
which therapeutic strategies remain empirical.2 Commonly, non- 
steroidal anti- inflammatory drugs (NSAIDs) and local corticoste-
roid injections are employed.3 Patients with PsA with dactylitis 
have higher disease activity and increased erosion risk.4–6 Guide-
lines by the Group for Research and Assessment of Psoriasis and 
Psoriatic Arthritis recommend conventional synthetic disease- 
modifying antirheumatic drugs (csDMARDs), such as meth-
otrexate (MTX), as a first- line on NSAIDs failure, but allow 
for expedited biologic disease- modifying antirheumatic drugs 
(bDMARDs) based on individual decisions.7 European League 
Against Rheumatism recommends the use of tumour necrosis 
factor inhibitors (TNFi) or biologics targeting interleukin 
(IL)-12/IL-23 or IL-17 pathways in patients with dactylitis that 
impacts function and quality of life.8
Across randomised controlled trials (RCTs) of bDMARDs 
efficacy in peripheral PsA, dactylitis has never been studied 
as a primary endpoint; current practice arises from the anal-
ysis of dactylitis as a secondary outcome.3 9 10 Golimumab, a 
human monoclonal antibody TNFi, has been approved for the 
treatment of active PsA.11 In GO- DACT, a phase 3b trial, we 
assessed the efficacy of golimumab in combination with MTX 
versus MTX monotherapy for improving psoriatic dactylitis as a 
primary endpoint.
MeTHOds
study design
GO- DACT was a multicentre, investigator- initiated, randomised, 
double- blind, placebo- controlled, phase 3b trial of golim-
umab plus MTX versus placebo plus MTX, in MTX- naive and 
bDMARDs- naive patients with PsA and active dactylitis. The 
study was conducted between August 2014 and June 2017 in 11 
rheumatology centres in Portugal. The protocol was previously 
published.12
Patients were centrally randomised in blocks of 4 (2:2) by 
computer- generated random sequence to receive subcutaneous 
injections of 50 mg golimumab or placebo, administrated every 
4 weeks for 24 weeks, both in combination with MTX. Patients 
and investigators were blind to treatment by providing identical 
prefilled syringes (MSD Pharmaceutics). MTX was started orally, 
15 mg/week and increased 5 mg every 4 weeks until a maximum 
dose of 25 mg/week, as tolerated. For gastrointestinal intoler-
ance, patients could be switched to a subcutaneous formulation. 
After the last golimumab injection, each subject was monitored 
for safety for 60 days (online supplementary figure 1). A planned 
interim efficacy analysis was performed when 50% of the esti-
mated recruitment had completed 24 weeks follow- up.
Patient population
Patients over 18 years of age with a diagnosis of PsA according 
to Classification for Psoriatic Arthritis criteria1 ≥1 digit with 
tender dactylitis and ≥1 other site of active inflammation (joints, 
enthesis, spine, skin or nails), naive to MTX and bDMARDs 
therapy and refractory to at least two NSAIDs at optimal dosage 
for 3 months were eligible for inclusion. Informed consent 
was obtained from all subjects before trial activity. The trial 
was conducted in accordance with the ethical principles of the 
Declaration of Helsinki, good clinical practice and approved by 
Portuguese Ethics Committee for Clinical Research, National 
Authority of Medicines and Health Products and National Data 
Protection Committee.
Key exclusion criteria were contraindications for the use of 
any TNFi or MTX, and factors that could interfere with trial 
evaluations or patient safety. A maximum of two previous 
local corticosteroids injections were allowed, administrated at 
least 4 weeks prior to screening. NSAIDs dose had to be stable 
throughout the trial. Cessation of other csDMARDs and corti-
costeroids, according to their recommended washout periods, 
was required.12
Trial procedures and endpoints
The primary endpoint was the change from baseline in Dactylitis 
Severity Score (DSS) at 24 weeks. Each digit with dactylitis was 
evaluated in a scale of 0–3 (0=no dactylitis, 1=mild dactylitis, 
2=moderate dactylitis, 3=severe dactylitis), where scores greater 
than 0 indicate the presence of dactylitis and the total score was 
calculated as the sum of scores for all 20 digits (0–60).13
Key secondary endpoints included the change from baseline in 
Leeds Dactylitis Index (LDI), based on the ratio of the circum-
ference of the affected digit and of the contralateral correspon-
dent digit, multiplied by a tenderness score (graded 0–3 on a 
Ritchie Index) for each digit with dactylitis14; and the number of 
patients with tender and non- tender dactylitis and with dactylitis 
remission (DSS=0). New dactylitis response indices, defined as 
the percentage of patients achieving at least 20%, 50% or 70% 
of improvement in the DSS (DSS20, 50 or 70); and as at least 
20%, 50% or 70% of improvement in the LDI (LDI20, 50 or 70) 
from baseline, were assessed in this trial. Enthesitis was evaluated 
resorting to the Leeds Enthesitis Index (LEI)15 and the Spondy-
loarthritis Research Consortium of Canada (SPARCC) enthesitis 
score.16 Enthesitis remission was defined as the absence of tender 
enthesis, according to LEI.
Additional key secondary endpoints comprised: 68 tender and 
66 swollen joint counts,17 patient- reported outcomes for global 
assessments of disease activity and pain and psoriasis evaluation 
using the Psoriasis Area Severity Index (PASI), Body Surface Area 
(BSA) score and Nail Psoriasis Severity Index (NAPSI) for the 
target nail. Other efficacy endpoints included physical function 
and health- related quality of life (psoriasis and global health), 
composite disease activity and response indices of PsA, as previ-
ously described.12 All clinical efficacy outcomes were collected at 
every trial visit by a trained rheumatologist blind to treatment.
High- resolution magnetic resonance imaging (MRI), providing 
better spatial resolution and anatomical definition, was performed 
for the most affected digit and conventional MRI of the corre-
sponding hand or foot, at baseline and week 24.12 Images were read 
by an experienced musculoskeletal radiologist, blind to treatment 
and chronologic sequence of images. High- resolution dactylitis 
images were scored according to the presence (0) or absence (1) 
of eight imaging features (synovitis, bone oedema, subcutaneous 
oedema, flexor tenosynovitis, extensor tenosynovitis, plantar/volar 
plate enhancement, collateral ligament enhancement and erosions), 
at the metacarpal/metatarsophalangeal (MCP/MTP), proximal 
interphalangeal (PIP) and distal interphalangeal (DIP) joints. The 
dactylitis total MRI score was calculated as the sum of the partial 
scores at each location, as previously described.18 The psoriatic 
arthritis MRI score (PSAMRIS), was used to assess the overall MRI 
changes in the hand (PSAMRIS- H)19 and foot (PSAMRIS- F).20 
A total of 37 patients performed paired MRIs of the hands (16 
patients) or feet (21 patients), and 36 patients paired high- resolution 
dactylitis images, according to the most active dactylitis location. 
Seven patients did not undergo hand/foot MRI and one other addi-
tionally high- resolution dactylitis protocol, due to MRI equipment 
failure/unavailability, inability to tolerate or trial discontinuation.
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Figure 1 GO- DACT trial consort flow diagram.
Safety and tolerability were evaluated and recorded 
throughout.
statistical analysis
We estimated that a sample size of 90 patients was required to 
detect a difference in DSS of 2.52 between groups (absolute 
change from GO- REVEAL trial), assuming a SD of 4.01, with a 
0.05 significance level, 80% power and accounting for a dropout 
rate of 10%.11 21 An interim analysis was planned when 50% 
of this sample size was included; when conducted, this detected 
favourable results for the primary endpoint. Based on these 
findings, patient inclusion was halted at this milestone. Effi-
cacy endpoints were assessed as changes from baseline or as the 
proportion of patients achieving responses at 12 and 24 weeks. 
An intention- to- treat analysis was performed for the primary 
endpoint, applying the last observation carried forward method 
and including all randomly assigned patients who received at 
least one dose of study medication. For the remaining clinical 
endpoints, a per- protocol analysis was conducted, taking into 
consideration that only two patients (one in each treatment arm) 
were lost to follow- up. For safety analysis, all patients receiving 
at least one dose of study medication were included. All statis-
tical analyses were done by a statistician blind to treatment. 
Continuous variables were summarised by median and inter-
quartile range (IQR), and comparisons were performed using the 
non- parametric Wilcoxon rank- sum test. Categorical variables 
were summarised by frequency and percentage, and significance 
of difference between the two arms analysed with Fisher’s exact 
test (including a generalised version for variables with more than 
two categories). All analyses were conducted using R V.3.5.0 
software (https://www. R- project. org).
resulTs
Patients disposition and baseline characteristics
A total of 44 patients with PsA enroled at 11 trial centres were 
randomised. Forty- two completed the study, with one patient 
on golimumab/MTX discontinuing due to an adverse event 
(asthma exacerbation), and another patient on placebo/MTX 
discontinuing due to an insufficient therapeutic effect (figure 1). 
The mean MTX dose of golimumab/MTX group was 16.3 mg/
week (range: 10–25 mg) and 19.2 mg/week (range: 15–25 mg) 
in MTX monotherapy group. Baseline demographics and disease 
activity were well matched; all patients had active dactylitis at 
baseline, with a median baseline DSS of 6 in both arms (table 1, 
online supplementary table 1).
Musculoskeletal efficacy
The primary efficacy endpoint was met, whereby patients treated 
with golimumab/MTX exhibited significantly greater improve-
ments by DSS at week 24 (median change of 5) relative to the 
placebo/MTX group (median change of 2) (p=0.026), and as early 
as 12 weeks (p=0.004; figure 2A). Key secondary analyses followed 
a similar pattern. The proportion of DSS50 and DSS70 responders 
at week 24 were significantly higher for patients treated with goli-
mumab/MTX (DSS50: p=0.005, DSS70: p=0.010; figure 2B). 
Greater improvements from baseline and in the proportion of 
LDI responders were observed in the golimumab/MTX group at 
24 weeks (figure 2C). The number of patients achieving dactylitis 
remission (DSS=0) was low in both treatment groups (6/20, 30% 
vs 4/22, 18.2%; table 2) and was not significantly different. A 
total of 66.7% (14/21) patients treated with golimumab/MTX 
and 21.7% (5/23) treated with MTX monotherapy had absence 
of tenderness (LDI tenderness=0) at 24 weeks, in the digits previ-
ously affected with dactylitis.
The median baseline dactylitis MRI score was balanced between 
arms: 8.5 (IQR 7) in the golimumab/MTX and 8.0 (IQR 10) in 
placebo/MTX. At week 24, we observed significantly lower scores 
in patients treated with golimumab/MTX than in those treated 
with placebo/MTX (p=0.017). The median change of dactylitis 
MRI score from baseline was numerically larger for golimumab/
MTX (5.5) in comparison with MTX monotherapy (3.5; p=0.273; 
table 3). Both golimumab/MTX and MTX monotherapy arms 
reduced bone oedema, subcutaneous oedema, volar and palmar/
plantar and collateral enhancement scores at the MCP/MTPs and 
PIPs, between baseline and week 24. These changes were numer-
ically more prevalent in golimumab/MTX group, but only signifi-
cantly different between treatment arms for synovitis and bone 
oedema at PIPs. No change in mean erosion score at the dactylitis 
digits was observed during the 24 weeks of treatment (table 3). At 
24 weeks, the absence of dactylitis associated- inflammatory lesions 
was observed in 31.0% (9/29) of all patients, 53.8% (7/13) of those 
receiving golimumab/MTX and 12.5% (2/16) of those receiving 
placebo/MTX.
GO- DACT patients had a median of 6.5/66 swollen and 
7.5/68 tender joints, and moderate Disease Activity Score 
four variables (DAS28 4v) or high Disease Activity in Psoriatic 
Arthritis (DAPSA) peripheral disease activity at baseline, despite 
the absence of inclusion criteria regarding the number of active 
peripheral joints. DAS28 4v, DAPSA and Psoriatic Arthritis 
Disease Activity Score (PASDAS) demonstrated improvements 
of disease activity in the golimumab/MTX in both week 12 
(p=0.004; p=0.012; p=0.0007) and week 24 (p=0.013, 
p=0.039; p=0.008; table 2, figure 2E) that were significantly 
greater than with placebo/MTX.
Overall, 36.4% (16/44) and 52.3% (23/44) of the patients had 
baseline enthesitis according to LEI and SPARCC, respectively. 
Median changes from baseline for both LEI and SPARCC and 
the percentage of patients with enthesitis remission at week 24 
were not significantly different between groups (table 2).
Cutaneous efficacy
PASI and BSA and skin- related quality of life (Dermatology Life 
Quality Index) improved in both groups at week 24. Patients 
in the golimumab/MTX arm demonstrated numerically but 
not significantly greater responses than placebo/MTX. Golim-
umab/MTX was also associated with improvements in the target 
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Table 1 Baseline demographic and disease characteristics of the study population
Characteristics study population n=44
GlM+MTX
n=21
Plb+MTX
n=23
Male gender, n (%) 37 (84.0%) 17 (81.0%) 20 (87.0%)
Age at randomisation, years, median (IQR) 45.7 (19.6) 46.2 (15.5) 44.1 (24.6)
Disease duration, median (IQR) 3.9 (6.9) 3.8 (6.7) 4.2 (6.1)
Body mass index (kg/m2), median (IQR) 26.6 (6.1) 29.0 (4.5) 25.9 (5.4)
Clinical subtype, n (%)
  Symmetric polyarthritis 9 (20.5) 5 (23.8) 4 (17.4)
  Predominant arthritis of the distal interphalangeal joints 3 (6.8) 2 (9.5) 1 (4.3)
  Asymmetric oligoarthritis 31 (70.5) 13 (61.9) 18 (78.3)
  Arthritis mutilans 0 (0) 0 (0) 0 (0)
  Predominant axial 1 (2.3) 1 (4.8) 0 (0)
Dactylitis
  DSS, median (IQR) 6 (4) 6 (5) 6 (3.5)
  LDI, median (IQR) 64.7 (81.7) 69.4 (73.8) 64.0 (100)
Enthesitis
  Enthesitis, median (IQR) 1 (2) 1 (2) 1 (2)
  Enthesitis ≥1 n (%) 23/44 (52.3%) 11/21 (52.4%) 12/23 (52.2%)
  LEI, median (IQR) 0 (1) 0 (1) 0 (1)
  LEI≥1, n (%) 16/44 (36.4%) 7/21 (33,3%) 9/23 (39,1%)
  SPARCC, median (IQR) 1 (2) 1 (2) 1 (2)
  SPARCC≥1, n (%) 23/44 (52.3%) 11/23 (47.8%) 12/23 (52.2%)
Peripheral joints
  Tender joints (68), median (IQR) 7.5 (9.25) 8 (9) 6 (8)
  Swollen joints (66), median (IQR) 6.5 (6.5) 7 (10) 6 (5)
Psoriasis
  PASI, median (IQR) 3.05 (4.3) 4 (4) 2.4 (2.65)
  BSA, median (IQR) 9.75 (21.6) 13 (29.5) 8.2 (15.3)
  Target NAPSI, median (IQR) 4 (8) 4 (10) 4 (5)
Physical function
  HAQ- DI, median (IQR) 0.875 (IQR) 0.875 (0.625) 0.875 (1.25)
Health- related quality of life
  DLQI, median (IQR) 3 (4.25) 4 (4) 1 (4)
Composite indices of disease activity
  DAS28 4v, median (IQR) 4.01 (1.68) 3.71 (0.96) 4.14 (1.99)
  DAPSA, median (IQR) 24.41 (21.31) 24.3 (20.84) 24.5 (20.20)
  PASDAS, median (IQR) 6.13 (2.35) 6.1 (1.83) 6.2 (2.58)
  CPDAI, median (IQR) 11 (I3.5) 11.0 (3.5) 11.5 (2.5)
BSA, body surface area; CPDAI, Composite Psoriatic Disease Activity Index; DAPSA, disease activity in psoriatic arthritis; DAS28 4v, Disease Activity Score 4 variablesDLQI, 
Dermatology Life Quality Index; DSS, Dactylitis Severity Score; GLM, golimumab; HAQ- DI, Health Assessment Questionnaire Disability Index; LDI, Leeds Dactylitis Index; LEI, Leeds 
Enthesitis Index; MTX, methotrexate; NAPSI, Nail Psoriasis Severity Index; PASDAS, Psoriatic Arthritis Disease Activity Score; PASI, Psoriasis Area and Severity Index; PLB, placebo; 
SPARCC, Spondyloarthritis Research Consortium of Canada Enthesitis Index;BSA, body surface area; BSA, body surface area; CPDAI, Composite Psoriatic Disease Activity Index; 
CPDAI, Composite Psoriatic Disease Activity Index; DAPSA, disease activity in psoriatic arthritis; DAPSA, disease activity in psoriatic arthritis; DAS28 4v, Disease Activity Score 4 
variablesDAS28 4v, Disease Activity Score 4 variablesDLQI, Dermatology Life Quality Index; DLQI, Dermatology Life Quality Index; DSS, Dactylitis Severity Score; DSS, Dactylitis 
Severity Score; GLM, golimumab; GLM, golimumab; HAQ- DI, Health Assessment Questionnaire Disability Index; HAQ- DI, Health Assessment Questionnaire Disability Index; LDI, 
Leeds Dactylitis Index; LDI, Leeds Dactylitis Index; LEI, Leeds Enthesitis Index; LEI, Leeds Enthesitis Index; MTX, methotrexate; MTX, methotrexate; NAPSI, Nail Psoriasis Severity 
Index; NAPSI, Nail Psoriasis Severity Index; PASDAS, Psoriatic Arthritis Disease Activity Score; PASDAS, Psoriatic Arthritis Disease Activity Score; PASI, Psoriasis Area and Severity 
Index; PASI, Psoriasis Area and Severity Index; PLB, placebo; PLB, placebo; SPARCC, Spondyloarthritis Research Consortium of Canada Enthesitis Index; SPARCC, Spondyloarthritis 
Research Consortium of Canada Enthesitis Index.
NAPSI, whereas no changes from baseline to week 12 or 24, 
were detected in placebo/MTX recipients (figure 2D).
response indices of disease activity
At week 24, patients’ improvement was numerically greater in 
the golimumab/MTX than placebo/MTX group for Minimal 
Disease Activity (MDA), Psoriatic Arthritis Response Criteria 
(PsARC) and Psoriatic Arthritis Joint Activity Index (PsAJAI). 
Statistically significant improvement was noted for American 
College of Rheumatology (ACR) 20 and ACR50 responses 
(figure 2F).
Imaging outcomes
MRI changes were described according to PSAMRIS- H and 
PSAMRIS- F. DIP readings were applicable only to the hands, 
and MCP/MTP and PIP readings were grouped together for 
hands and feet. Osteoproliferation at MTPs/PIPs and periartic-
ular inflammation at PIPs of the feet were excluded due to low 
image resolution. Golimumab/MTX delivered greater reduction 
in PSAMRIS inflammatory lesion scores between baseline and 
week 24, but these differences were only significant in compar-
ison with placebo/MTX for changes in PIP synovitis. Bone 
erosion and proliferation did not differ significantly between 
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Figure 2 Changes from baseline to week 24 in DSS (A), psoriasis disease activity (D) and composite disease activity indices (E). Proportion of 
responders at week 24 of DSS 20, 50 and 70 (B), LDI 20, 50 and 70 (C) and response indices (F). ACR, American College of Rheumatology response 
index; BSA, body surface area; CDAI, clinical disease activity index; CPDAI, composite psoriatic disease activity index; DSS, Dactylitis Severity Score; 
DAPSA, disease activity in psoriatic arthritis; DAS28 4v, Disease Activity Score four variables; LDI, Leeds Dactylitis Index; MDA, minimal disease activity; 
MTX, methotrexate; NAPSI, Nail Psoriasis Severity Index; PASDAS: Psoriatic Arthritis Disease Activity Score; PASI: Psoriasis Area and Severity Index; 
PsAJAI, Psoriatic Arthritis Joint Activity Index; PsARC, Psoriatic Arthritis Response Criteria; SDAI, simplified disease activity index. *p<0.05; **p<0.005; 
***p<0.001.
timepoints, regardless of location or treatment (table 4, online 
supplementary table 3). At 24 weeks, resolution of inflammation, 
defined as a PSAMRIS of 0 (excluding erosions and bone prolif-
eration), was achieved by 12 patients; 50% (7/14) of patients in 
golimumab/MTX and 29.4% (5/17) in MTX monotherapy.
safety
One hundred and two adverse events were reported during the 
GO- DACT study period, mostly of mild to moderate severity, 
overall with similar incidence between treatment arms. There 
were no new safety issues during this trial.
dIsCussIOn
Herein we show that the combination of golimumab plus MTX 
is associated with significantly greater clinical improvements 
in dactylitis activity than MTX monotherapy. GO- DACT also 
demonstrated that the application of innovative DSS and LDI 
response indices (DSS20/50/70 and LDI20/50/70) discriminated 
between treatment arms, as early as 12 weeks, despite the small 
trial size. DSS and LDI response indices might be useful instru-
ments for future trials assessing dactylitis. We also observed 
a trajectory for DSS and LDI response from week 12 to 24 
commensurate with a slower achievement of maximal dactylitis 
response. This has been observed in RCTs with longer follow- up 
periods11 ; evaluation of complete resolution of dactylitis in 
future trials may require follow- up longer than 24 weeks. The 
follow- up of these patients, according to clinical practice, might 
bring additional information on the long- term dactylitis remis-
sion rates.
Improvements favouring the golimumab plus MTX group 
occurred across other than dactylitis PsA domains including 
peripheral arthritis, nail psoriasis and composite measures 
of disease activity (DAS28 4v, DAPSA and PASDAS). PASDAS 
showed the ability to discriminate between treatment arms and 
performed better than the Clinical Disease Activity Index (CDAI), 
reinforcing previously published golimumab trials and ‘real- 
world’ data, suggestive of larger effect sizes for PASDAS.22 23 Nail 
psoriasis has not been frequently studied in PsA RCTs.24–26 Here, 
we showed significant benefit from golimumab plus MTX and an 
absence of improvement of target NAPSI in MTX monotherapy- 
treated patients, supporting previously reported lack of efficacy 
of MTX.27 Others though have described improvement of the 
nail matrix component with MTX.28
We included an exploratory imaging evaluation. Evidence that 
either TNFi or MTX can ameliorate hand/feet PsA MRI features 
is limited. Both golimumab plus MTX and MTX monotherapy 
reduced articular and periarticular inflammatory scores either on 
dactylitis and overall PSAMRIS, while erosions and osteopro-
liferation scores remained globally unchanged throughout the 
24 weeks of the trial. Due to slow progression, erosions or new 
bone formation changes in PsA are difficult to depict in short- 
term studies, and MRI complete resolution of inflammation 
remains a challenging target.29
We studied an MTX- naive population to avoid bias from 
MTX prior non- responders. Although less efficacious alone than 
in combination with golimumab, we observed small improve-
ments in dactylitis (−2 DSS units from baseline to week 24) 
and other PsA domains (peripheral arthritis and plaque psori-
asis) in MTX monotherapy- treated patients. Furthermore, 
MTX monotherapy patients consistently attained higher rates 
of response from week 12 to week 24 for peripheral arthritis 
and composite indices (ACR, MDA, PsARC, PsAJAI, PASI) of 
PsA activity, suggesting incremental therapeutic benefits that 
continued through follow- up. These results are in line with a 
recently published RCT showing moderate but consistent bene-
fits from MTX.30
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Table 2 Efficacy outcomes change from baseline to week 12 and 24, for both treatment arms
efficacy outcomes
12 Weeks 24 Weeks
Median change
GlM+MTX
Median change
Plb+MTX P value
Median change
GlM+MTX
Median change
Plb+MTX P value
Dactylitis
  DSS -3.5 -1 0.004 -5 -2 0.026
  DSS response
  DSS 20, n (%) 19/20 (95) 12/23 (52.2) 0.002 19/20 (95.0) 16/22 (72.7) 0.096
   DSS 50, n (%) 17/20 (85) 7/23 (30.4) 0.001 17/20 (85.0) 09/22 (40.9) 0.005
   DSS 70, n (%) 7/20 (35) 5/23 (21.7) 0.497 12/20 (60.0) 4/22 (18.2) 0.010
  Dactylitis remission (DSS=0), n (%) 2/20 (10) 4/23 (17.4) 0.67 6/20 (30.0) 4/22 (18.1) 0.477
  LDI -58.6 -34.6 0.169 -69.4 -31.1 0.042
  LDI response
   LDI 20, n (%) 19/19 (100.0) 18/23 (78.3) 0.053 19/19 (100.0) 16/22 (72.7) 0.023
   LDI 50, n (%) 17/19 (89.5) 13/23 (56.5) 0.037 19/19 (100.0) 15/22 (68.2) 0.001
   LDI 70, n (%) 16/19 (84.1) 9/23 (39.1) 0.004 18/19 (94.7) 9/22 (40.9) 0.011
Enthesitis
  Enthesitis -0.5 0 0.512 -1 0 0.224
  LEI 0 0 0.752 0 0 0.953
  SPARCC -0.5 0 0.589 -1 0 0.216
  Enthesitis remission (LEI=0), n (%) 9/11 (81.8) 10/12 (83.3) 11/11 (100.0) 9/11 (90.0) 0.476
Peripheral joints
  Tender joints (68) -5.5 -2 0.026 -7.5 -5 0.077
  Swollen joints (66) -6.5 -2 0.006 -7 -4 0.060
Psoriasis
  PASI -2.4 -0.6 0.027 -2.2 -1.1 0.130
  BSA -7 -0.5 0.097 -5.8 -2.5 0.337
  Target NAPSI -2 0 0.044 -1.5 0 0.027
Patient- reported and physician- reported outcomes
  PGA for arthritis activity (0–100 mm) -20 -12.5 0.874 -34 -16.5 0.190
  PGA for psoriasis activity (0–100 mm) -30 -10 0.846 -10 -9 0.860
Physical function
  HAQ- DI -0.5 -0.125 0.163 -0.375 -0.188 0.414
Health- related quality of life
  DLQI -2 -0.5 0.101 -2.5 -1 0.161
Composite indices of disease activity
  DAS28 4v -1.67 -0.83 0.004 -1.72 -1.15 0.013
  DAPSA -17.05 -9.32 0.012 -21.62 -12.88 0.039
  PASDAS -2.7 -1.39 0.001 -3.27 -1.76 0.008
  CPDAI -2 -2 0.312 -6 -3 0.292
Response indices
  ACR
   ACR 20, n (%) 17/17 (100.0) 9/19 (47.4) 0.001 15/16 (93.8) 12/19 (63.2) 0.047
   ACR 50, n (%) 11/19 (57.9) 5/21 (23.8) 0.052 12/17 (70.6) 7/21 (33.3) 0.049
   ACR 70, n (%) 6/20 (30.0) 1/22 (4.5) 0.041 8/19 (42.1) 5/22 (22.7) 0.313
  MDA, n (%) 10/18 (55.6) 3/23 (13.0) 0.006 11/16 (68.8) 9/21 (42.9) 0.185
  PsARC, n (%) 16/20 (80.0) 13/23 (56.5) 0.119 17/20 (85.0) 16/22 (72.7) 0.460
  PsAJAI, n (%) 16/18 (88.9) 14/22 (63.6) 0.082 16/17 (94.1) 16/21 (76.2) 0.197
  PASI
   PASI 50, n (%) 16/20 (80.0) 10/22 (45.5) 0.029 17/20 (85.0) 12/20 (60.0) 0.155
   PASI 70, n (%) 10/20 (50.0) 8/22 (36.4) 0.534 12/20 (60.0) 9/20 (45.0) 0.527
   PASI 90, n (%) 5/20 (25.0) 4/22 (18.2) 0.714 5/20 (25.0) 8/20 (40.0) 0.501
ACR, American College of Rheumatology; BSA, body surface area; CPDAI, Composite Psoriatic Disease Activity Index; DAPSA, Disease Activity in Psoriatic Arthritis; DAS28 v4, Disease Activity Score four variables; DLQI, 
Dermatology Life Quality Index; DSS, Dactylitis Severity Score; GLM, golimumab; HAQ- DI, Health Assessment Questionnaire Disability Index; LDI, Leeds Dactylitis Index; LEI, Leeds Enthesitis Index; MDA, minimal disease 
activity; MTX, methotrexate; NAPSI, Nail Psoriasis Severity Index; PASDAS, Psoriatic Arthritis Disease Activity Score; PASI, Psoriasis Area and Severity Index; PGA, patient global assessment; PhGA, physician global 
assessment; PLB, placebo; PsAJAI, Psoriatic Arthritis Joint Activity Index; PsARC, Psoriatic Arthritis Response Criteria; SPARCC, Spondyloarthritis Research Consortium of Canada Enthesitis Index.p<0.05.
Global assessment of safety on golimumab plus MTX was as 
expected.31
Considering the high disease burden of dactylitis in patients 
with PsA, including a lower chance of achieving MDA6 and the 
risk of structural damage,4 5 and advantages of early TNFi inter-
vention,32 it seems reasonable to argue that patients with PsA 
active dactylitis could benefit from first- line TNFi plus MTX 
therapy. We expect that these results will be reproducible with 
other TNFi combination therapies.33
Limitations in our study include the small number of 
patients enroled, which can increase the risk of type II errors. 
However, because the primary endpoint showed significant 
differences between treatment groups, recruitment was halted 
at half of the planned enrolment. MRI assessment was included 
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Table 4 PSAMRIS for individual MRI features as assessed by PSAMRIS- H and PSAMRIS- F, for both treatment arms, at baseline and change from 
baseline to week 24
PsAMrIs features
MCP/MTP PIP dIP
GlM+MTX Plb+MTX GlM+MTX Plb+MTX GlM+MTX Plb+MTX
baseline Change baseline Change baseline Change baseline Change baseline Change baseline Change
Synovitis, mean 3.8 −2.87 3.44 −1.94 1.93 −1.54* 1.06 0 1 −0.67 1 −0.71
(observed range) (0 to 12) (−9 to 0) (0 to 7) (−7 to 2) (0 to 4) (−4 to 1) (0 to 3) (−3 to 3) (0 to 3) (−2 to 0) (0 to 4) (-2 to 0)
Flexor tenosynovitis, mean 0.56 −0.38 0.47 −0.05 0.56 −0.38 0.47 −0.05 1.4 −1 1 −0.33
(observed range) (0 to 3) (−2 to 0) (0 to 3) (−2 to 2) (0 to 3) (−2 to 0) (0 to 3) (−2 to 2) (0 to 3) (−2 to 0) (0 to 3) (-2 to 2)
Periarticular inflammation, mean 3.14 −1.86 3 −2.41 0.33 0 0.33 0.14 0.6 −0.4 0.5 −0.29
(observed range) (0 to 24) (−14 to 0) (0 to 7) (−7 to 0) (0 to 2) (0 to 0) (0 to 2) (0 to 1) (0 to 2) (−1 to 0) (0 to 2) (-1 to 0)
Bone marrow oedema, mean 4.56 −2.94 3.11 −2.67 4.82 −3.59 3 −0.72 1.33 −1 2 -1
(observed range) (0 to 23) (−14 to 0) (0 to 16) (−16 to 0) (0 to 24) (−22 to 1) (0 to 16) (−8 to 4) (0 to 6) (−6 to 0) (0 to 8) (-4 to 0)
Bone erosion, mean 2.06 0.5 1.47 −0.06 1.47 0 1.53 0.89 6.33 0 2.89 0
(observed range) (0 to 12) (−3 to 12) (0 to 8) (−2 to 1) (0 to 13) (0 to 0) (0 to 14) (−1 to 10) (0 to 14) (0 to 0) (0 to 8) (0 to 0)
Bone proliferation, mean 2.83 0 1.67 0 2.67 0 2.67 0 2.2 −0.8 2 0
(observed range) (0 to 5) (0 to 0) (0 to 5) (0 to 0) (0 to 5) (0 to 0) (0 to 5) (0 to 0) (0 to 4) (−4 to 0) (0 to 4) (0 to 0)
*Difference between treatment groups in the change from baseline to week 24 (p=0.0054); p<0.05.
DIP, distal interphalangeal joints; GLM, golimumab; MCP/MTP, metacarpal/metatarsophalangeal joints; MTX, methotrexate; PIP, proximal interphalangeal joints; PLB, placebo; PSAMRIS, Psoriatic 
Arthritis MRI Score; PSAMRIS- F, Psoriatic Arthritis MRI Score for the foot.; PSAMRIS- H, Psoriatic Arthritis MRI Score for the hand.
as a secondary exploratory endpoint in a limited number of 
patients with single imaging reading, which implies caution 
in data interpretation. Although a golimumab monotherapy 
arm could also have been included, results from GO- REVEAL 
suggested a 10% additional benefit in dactylitis improvements 
from combination with MTX. GO- DACT included several 
variables to capture disease activity in its different domains, 
increasing the risk of type I error through multiple compari-
sons. Nevertheless, the population was well- balanced between 
groups, and results were consistent between the variables and 
with the published literature. This was potentiated by the lack 
of consensus, especially regarding composite disease activity 
scores.
COnClusIOns
GO- DACT provides strong evidence that combination of 
golimumab plus MTX is more efficacious than MTX mono-
therapy in improving PsA dactylitis. GO- DACT also exempli-
fied that application of the innovative DSS and LDI response 
indices (DSS20, 50 and 70 and LDI20, 50 and 70) allowed 
discrimination between treatment arms, which could be useful 
for future PsA trials.
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